Public Profile

Zogenix, Inc.

Zogenix, Inc., a prominent biopharmaceutical company headquartered in the United States, focuses on developing and commercialising innovative therapies for patients with rare neurological diseases. Founded in 2013, Zogenix has made significant strides in the industry, particularly with its flagship product, Fintepla, which is designed to treat Dravet syndrome, a severe form of epilepsy. With a commitment to addressing unmet medical needs, Zogenix operates primarily in the US and has expanded its reach to international markets. The company is recognised for its unique approach to drug development, leveraging advanced formulations to enhance patient outcomes. Zogenix's dedication to innovation and patient care has solidified its position as a leader in the biopharmaceutical sector, earning accolades for its contributions to the treatment of complex neurological disorders.

DitchCarbon Score

How does Zogenix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Zogenix, Inc.'s score of 13 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Zogenix, Inc.'s reported carbon emissions

Zogenix, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As a result, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is unclear how Zogenix is addressing climate change or contributing to sustainability efforts within the pharmaceutical industry.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Zogenix, Inc.'s primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Zogenix, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Zogenix, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Eternity Healthcare, Inc.

HK
Health and social work services (85)
Updated 5 days ago

Crossject Société Anonyme

FR
Medical, precision and optical instruments, watches and clocks (33)
Updated 5 days ago

GW Pharmaceuticals Limited

GB
Health and social work services (85)
Updated 5 days ago
DitchCarbon Score

Collegium Pharmaceutical, Inc.

US
Chemicals nec
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers